UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2017
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware
|
|
001-16407
|
|
13-4151777
|
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
345 East Main Street
Warsaw, Indiana 46580
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code:
(574) 267-6131
Not applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of
this chapter).
Emerging growth
company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the
extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
On July 21, 2017, Zimmer Biomet Holdings, Inc. (the
“Company”) announced that Adam R. Johnson, Group President for the Spine, Dental, Craniomaxillofacial and Thoracic business units, will resign effective September 1, 2017. Mr. Johnson informed the Company that, with the
integration of LDR substantially complete and new leaders in place in Zimmer Biomet’s Spine and Dental business units, his decision was motivated by his desire to pursue his professional goals that include a career in private equity. Chris
Jefferis, Vice President of Finance for Spine, Dental, Craniomaxillofacial and Thoracic, will serve as the Interim Group President until a permanent successor has been named. Mr. Jefferis will report directly to Daniel Florin, Interim Chief
Executive Officer, Senior Vice President and Chief Financial Officer.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: July 21, 2017
|
|
|
|
|
ZIMMER BIOMET HOLDINGS, INC.
|
|
|
|
|
By:
|
|
/s/ Chad F. Phipps
|
|
Name:
|
|
Chad F. Phipps
|
|
Title:
|
|
Senior Vice President, General Counsel
|
|
|
|
and Secretary
|
